Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did anyone listened to today's ADXS teleconference? Can you please volunteer ti provide some data and your opinion?
"I believe ADXS has more potential than Ariad had. I'm just worried about the cash burn."
Thanks for the post heldnova, I'm glad to hear of ADXS potential from a previous biotech jackpot hitter!
My take on the ADXS Report:
Pipeline:
Nothing new mentioned in terms of pipeline updates (all old info).... I like Dew's post that there is a possibility of press release tomorrow morning.
Financial:
burn rate was high in 2017 due to one time charges such as phase 3 trail and EU Application, etc.
Furthermore, future trials have me trimmed and more focused, and burn rate will be much lower than 2017, thus ADXS would have enough cash to run into 2019
Thanks bybtrader, any idea of approximately when approvals are expected?
But there was one patent application approval pending? Which one is that?
When do you think Australian Patent news is coming? Approximately how long?
I agree with mypekeispooped's total agreement of disagreement by Chemist823, and bourbon insinuating his agreement of Chemist's disagreement....
There, it's all out now and I feel much better.
"Hopefully 3.27 we be the new support"
Yep, that is the new support according to intraday chart so far!
ADXS has broken past its 50-Day Moving average of $3.27....
I would expect HFT & Algos to be on our side now.... they should follow logic!
PETX wins conditional approval for treating canine osteosarcoma:
https://finance.yahoo.com/news/aratana-therapeutics-granted-conditional-license-130500431.html
"The imaginary HFT is trying hard to squash this"
And that's where tonight Earning Release and tomorrow's conference comes in... COME'ON LOMBARDO.... DELIVER SHAREHOLDER VALUE!
"It's amazing at the moment, there's a fight going on to not let the PPS go above $ 3.37!"
Looks like ADXS passed its "Red on good news" disease to PETX lol
ADXS made a new monthly high! Up we go!
"Bought another 1000 shares premarket at $3.15 today, I hope it explodes, not implodes. GLTA."
Same here, just bought 1000 ADXS shares
ADXS LM finally hit market, this is priceless to us longs....
If price implodes, it doesn't matter, it is reason to buy more ADXS today and that's exactly what I plan on doing!
Poll:
If you had some fresh money, would you buy more ADXS before 12/21/17 Earnings Release or After?
Why?
Biotech Overseas Cash as of third quarter 2017:
Amgen. $39 Billion
Gilead. $32 Billion
Pfizer. $22 Billion
Merk. $20 Billion
J&J. $14 Billion
Eli Lilly. $12 Billion
AbbVie. $10 Billion
BMY. $9 Billion
Celgene. $9 Billion
Biogen. $4 Billion
Biotech Overseas Cash as of third quarter 2017:
Amgen. $39 Billion
Gilead. $32 Billion
Pfizer. $22 Billion
Merk. $20 Billion
J&J. $14 Billion
Eli Lilly. $12 Billion
AbbVie. $10 Billion
BMY. $9 Billion
Celgene. $9 Billion
Biogen. $4 Billion
Next year will be third year in a row I would look like an idiot to my tax accountant cuz if ADXS :(
Comeone AT-014 and Dec21 update... help us break single digits already!!!!!
Just saw AVXS at $103+.... why can't ADXS be like that? Only one alphabet off lol
I'm more curious about AT-014, and PETX has so much more in the pipeline, so no worries on ST-014 failure
"If the stock is at $5 or less on Oct 15 2018, the company will get $0 from the warrants as they will be worthless and not exercised."
So it would be in ADXS Management's best interests to make sure ADXS is above $5 by October 2018.
Business Rule #1: Never say no to money!
So dilution may not be imminent considering money from AMGN, SELLAS, Stendhal & $5/Warrants in 2018...
ADXS quarterly statements mentioning cash running into 2019 has validity....
Why is the market giving out $3 for ADXS? This is messed up
So October 2018, ADXS is getting all the warrants revenue at $5?
Does that mean more Cash on Hand?
"There is no deal to announce next week. Stop giving false hope. It is an earnings release. Plain and simple.
Most likely early to clean the slate for 2018. Get the bad stuff behind us and move forward."
Agreed, just another earning release. Historically, ADXS has never thrown a surprise update in conferences and updates....
If there is any news, I would expect it before 12/21/17 to an SEC submission...
Thanks hovacre, I think I reached my learning limit for today lol
"But researchers can't really identify a single mutation or aberration in many cases that is selective to the tumor cell (and is not found naturally in the body, which is why HPV is already a theoretically sound target)."
Confused about the above statement: So does HPV has single mutation that can be identified?
Hovacre, a little more help please, did I get the following right? If not how would you correct it?
Basic Background:
1. T-Cells rely on receptor cells to identify tumor/bad cells.
2. T-Cells kill tumor/bad cells to destroy cancer.
CAR-T Technology:
Manmade Artificial T-Cell Receptors guide CAR-T cells to destroy tumor/bad cells.
ADXS LM NEO:
1. Bioengineered bacteria is injected, which is eaten/enters the body's natural receptor cells (known as Antigen Presenting Cells).
2. After entering, LM secrets the cancer specific antigen (stuff needed to kill tumor/bad cells) into the receptor cell.
3. Receptor cells uses that LM secreted antigen to guide T-Cells to find that specific tumor/bad cells and destroy it.
According to slide 12 of ADXS Corporate Presentation, LM Technology will overtake CAR-T:
1980s: Cancer Vaccines
2014: Immune Checkpoint Inhibitors
2017: CAR-T
(Future): LM Technology
Lombardo's statements do include the keyword "shareholder value"... let's see if he says that keyword again and what the plans are for delivering "shareholder value".
Thanks hovacre, I will be reading this a few more times to better understand this (rookie at biotech vocabulary lol).
Hovacre,
In your opinion, how is CAR-T different from NEO?
I heard one response as CAR-T is a cell based therapy...
Yea, closed right on the resistance.... $3.20 is going to be the next support or resistance depending on tomorrow's performance....
A green close with somewhat higher than average volume today is good enough for now
Nice! I'm getting more powder end of this week and anything in single digits is an F'ed Up Beyond All Believes kind of bargain.... lol
"However, we note that Advaxis’ Lm technology products have multiple copies of tLLO-fusion protein in each plasmid compared to a single copy of the target gene for Aduro. Multiple tLLO copies secrete the target protein directly inside of APCs to elicit an immune response, which is expected to be stronger than using a single copy of the target
gene. "
So ADXS LM is the beast!
I see $3.24 as the barrier (last chart peak).... hoping it breaks that
I don't mean to be repetitive... but WTH is this... ADRO is green on news of its price target cut in half from $18 to $9.5?
Dew,
What's the difference between CAR-T and Neo?
And yea what's up with that... ADRO's price target cut by half and its share price doesn't budge...
"All of the OWCP patent applications have been rejected.
There won't be any patents in June. That is wishful thinking only. "
So OWCP has no patents to date? Anyone know how the pending patent submission is different from previous patent submissions?